Home » Jeffrey Radding

Jeffrey Radding

Feb 15, 2007
Premium
Jeffrey Radding has joined Epitome Biosystems as vice president for research and development, the company announced this week.
 
Prior to joining Epitome, Radding headed the Platform Biology Group at Eli Lilly. The group evaluated and implemented cell signaling approaches for drug discovery across multiple therapeutic areas.
 
Radding obtained his PhD in chemistry from Indiana University.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

The Scan

Last of the Northern White Rhinoceroses, Sequenced

Researchers have sequenced the northern white rhinoceros to gauge whether it could be brought back from the edge of extinction, the New York Times reports.

DNA Phenotyping Allowed in Bavaria

Bavaria expands its forensic genetic analyses to include DNA phenotyping, raising discrimination concerns.

Thanks for the Stress, Dad

Tufts University researchers found a role for miRNA in transmitting stress between generations, the Economist reports.

This Week in Science

In Science this week: gut microbiome influences liver cancer growth, spread; and more.

Jun
19
Featured Webinar

RNA in situ Hybridization: The Next Generation of Immunohistochemistry?

Sponsored by
Advanced Cell Diagnostics

This webinar will provide evidence for the use of RNA in situ hybridization (RNA ISH) as a replacement for immunohistochemistry (IHC) in cancer research and diagnostic applications.

What's Popular?

In Proteomics & Protein Research

  1. Study Highlights HeLa Cell Heterogeneity

    Premium

  2. Lung Cancer Study Investigates Role of Protein Modifications in Cell Signaling, Drug Response

    Premium

  3. Open Medicine Foundation Commits $1.8M to Research ME/CFS at Harvard Hospitals

  4. Rutgers Team Devises Multi-Stage Antibody Development Workflow

    Premium

Sponsorships

Privacy Policy.  Terms & Conditions.  Copyright © 2018 GenomeWeb LLC.  All Rights Reserved.